About The Study: The convergent data in this study support a prospective clinical trial of low-dose lithium orotate to slow disease progression in mild cognitive impairment. Such an approach would prioritize established neuroprotective mechanisms while potentially mitigating the kidney and thyroid risks associated with higher-dose carbonate formulations. If low-dose lithium can indeed meaningfully alter disease trajectory, it would represent a much-needed, accessible, and inexpensive treatment that may be especially relevant in low- and middle-income countries.
Corresponding Author: To contact the corresponding author, Husseini K. Manji, MD, email husseini.manji@psych.ox.ac.uk.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(10.1001/jamapsychiatry.2026.1296)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.1296?guestAccessKey=11f24b55-4e87-4918-ab66-bf4a155ce272&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061026
Journal
JAMA Psychiatry